Form 4: NewAmsterdam Pharma Co N.V. Director Acquires Options
SEC Form 4 Filing
Mark C. McKenna, a director of NewAmsterdam Pharma Co N.V., acquired options to purchase 72,500 ordinary shares on July 17, 2024.
Summary
- Mark C. McKenna, a director of NewAmsterdam Pharma Co N.V., filed a Form 4 to report changes in beneficial ownership.
- On July 17, 2024, McKenna acquired options to purchase 72,500 ordinary shares at an exercise price of $18.81.
- These options vest over three years, with 33% vesting on July 17, 2025, and the remainder vesting in equal monthly installments thereafter, contingent upon continued service.
- Following the transaction, McKenna directly owns options for 72,500 ordinary shares.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing an insider transaction. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company directors.
Stakeholder Impact
- The transaction could be perceived positively by shareholders as it indicates confidence from a director in the company's future.
Key Dates
| Date | Description |
|---|---|
| 07/17/2024 | Date of transaction: Director acquired options to purchase shares. |
| 07/17/2025 | Vesting start date: 33% of the options will vest. |
| 07/17/2034 | Expiration date of the options. |
| 07/19/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.